An Investigational Scan (FAP-2286 PET) for the Imaging of Solid Tumors

Inclusion Criteria

• Age >= 18 years
• Histopathologically confirmed solid tumors in one of the following cohorts * Cohort 1 (n=11): measurable disease is not required for this cohort ** Agnostic to tumor type * Cohort 2 (n=95): Metastatic disease present on conventional imaging* defined as having Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease or multiple bone metastases * Presence or absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for the study ** Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, or colon cancer ** Pathologically confirmed cancer other than noted above (basket subgroup, n=10) * Cohort 3 (n=85): No evidence of metastatic disease* as defined as the absence of RECIST 1.1 measurable disease or bone metastases * Presence or absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for the study ** Patients can be imaged at initial staging with what is judged by the treating physician to be high-risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Patients may also be imaged after definitive therapy (surgery, chemotherapy, or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis ** Pathologically confirmed head and neck cancer or bladder cancer
• Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria

• Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation
• Known pregnancy